A Şahin1, Z Gürsel-Özkurt2, M Şahin2, F M Türkcü3, A Yıldırım4, H Yüksel5. 1. Department of Ophthalmology, Batman Private Hospital, Batman, Turkey. dralparslansahin@gmail.com. 2. School of Medicine, Department of Ophthalmology, Dicle University, Diyarbakır, Turkey. 3. Department of Ophthalmology, Batman Zilan Hospital, Batman, Turkey. 4. Department of Ophthalmology, Yeni Hayat Hospital, Osmaniye, Turkey. 5. Frelance Physician, Diyarbakır, Turkey.
Abstract
AIM: We aimed to investigate the effectivity of the 0.0625 mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625 mg dose of intravitreal bevacizumab (IVB) injection. METHODS: The medical records of the patients with type 1 ROP who received IVB monotherapy were retrospectively reviewed. Demographic and clinical characteristics of the patients were recorded. The patients were classified into two groups with respect to received dose of bevacizumab as follows: group F (n = 46) (full dose of bevacizumab-0.625 mg/0.025 ml) and group L (n = 45) (low dose (one tenth) of bevacizumab-0.0625 mg/0.025 ml). RESULTS: Both treatment dose regimens have similar outcomes. Moreover, the mean retinal vascularization time seemed to be significantly higher in group F compared to group L, 168 ± 65 and 97 ± 29 days, respectively (p < 0.001). Disappearance of plus sign is observed earlier in group F (2.45 ± 1.7 vs 3.66 ± 2.46 days, respectively, p = 0.03). CONCLUSIONS: The low dose (0.0625 mg) of IVB treatment was effective as full (0.625 mg) dose in ROP treatment. Moreover, our results showed that low-dose treatment might provide faster retinal vascularization than the regular used dose. On the other hand, disappearance of the plus sign takes longer time in patients treated with low dose compared to eyes treated with full dose of IVB that should be taken into account.
AIM: We aimed to investigate the effectivity of the 0.0625 mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625 mg dose of intravitreal bevacizumab (IVB) injection. METHODS: The medical records of the patients with type 1 ROP who received IVB monotherapy were retrospectively reviewed. Demographic and clinical characteristics of the patients were recorded. The patients were classified into two groups with respect to received dose of bevacizumab as follows: group F (n = 46) (full dose of bevacizumab-0.625 mg/0.025 ml) and group L (n = 45) (low dose (one tenth) of bevacizumab-0.0625 mg/0.025 ml). RESULTS: Both treatment dose regimens have similar outcomes. Moreover, the mean retinal vascularization time seemed to be significantly higher in group F compared to group L, 168 ± 65 and 97 ± 29 days, respectively (p < 0.001). Disappearance of plus sign is observed earlier in group F (2.45 ± 1.7 vs 3.66 ± 2.46 days, respectively, p = 0.03). CONCLUSIONS: The low dose (0.0625 mg) of IVB treatment was effective as full (0.625 mg) dose in ROP treatment. Moreover, our results showed that low-dose treatment might provide faster retinal vascularization than the regular used dose. On the other hand, disappearance of the plus sign takes longer time in patients treated with low dose compared to eyes treated with full dose of IVB that should be taken into account.
Entities:
Keywords:
Intravitreal bevacizumab; Low dose; Retinal vascularization; Retinopathy of prematurity
Authors: Alparslan Şahin; Muhammed Şahin; Abdullah Kürşat Cingü; Yasin Çınar; Fatih Mehmet Türkcü; Harun Yüksel; Savaş Kaya; Şeyhmus Arı; İhsan Caça Journal: Pediatr Int Date: 2013-07-30 Impact factor: 1.524
Authors: Ann Hellström; Eva Engström; Anna-Lena Hård; Kerstin Albertsson-Wikland; Björn Carlsson; Aimon Niklasson; Chatarina Löfqvist; Elisabeth Svensson; Sture Holm; Uwe Ewald; Gerd Holmström; Lois E H Smith Journal: Pediatrics Date: 2003-11 Impact factor: 7.124
Authors: Jingyun Wang; Xiaowei Ren; Li Shen; Susan E Yanni; Joel N Leffler; Eileen E Birch Journal: Invest Ophthalmol Vis Sci Date: 2013-09-05 Impact factor: 4.799